Clinical trials in neurosurgical oncology

Meghan Murphy, Ian F Parney

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Brain tumors such as diffuse infiltrating gliomas continue to represent a major clinical challenge. Overall survival for patients diagnosed with glioblastoma, the most common primary brain tumor, remains less than 2 years despite intensive multimodal therapy with surgery, radiation, and chemotherapy. However, advances have been made in standard therapies and novel treatments that are showing great potential. These advances reflect careful study performed in the context of clinical trials. Neurosurgeons have played and will continue to play key parts in these studies. In this manuscript, we review clinical trials in neuro-oncology from a neurosurgical point of view and discuss potential roles for neurosurgeons in advancing glioma therapy in the future.

Original languageEnglish (US)
Pages (from-to)569-576
Number of pages8
JournalJournal of Neuro-Oncology
Volume119
Issue number3
DOIs
StatePublished - Sep 20 2014

Fingerprint

Clinical Trials
Brain Neoplasms
Glioma
Therapeutics
Glioblastoma
Radiation
Drug Therapy
Survival
Neurosurgeons

Keywords

  • Brain tumor
  • Clinical trial
  • Glioblastoma
  • Glioma
  • Surgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Clinical trials in neurosurgical oncology. / Murphy, Meghan; Parney, Ian F.

In: Journal of Neuro-Oncology, Vol. 119, No. 3, 20.09.2014, p. 569-576.

Research output: Contribution to journalArticle

Murphy, Meghan ; Parney, Ian F. / Clinical trials in neurosurgical oncology. In: Journal of Neuro-Oncology. 2014 ; Vol. 119, No. 3. pp. 569-576.
@article{416d1f9ab35e46dc95f27b94838a016c,
title = "Clinical trials in neurosurgical oncology",
abstract = "Brain tumors such as diffuse infiltrating gliomas continue to represent a major clinical challenge. Overall survival for patients diagnosed with glioblastoma, the most common primary brain tumor, remains less than 2 years despite intensive multimodal therapy with surgery, radiation, and chemotherapy. However, advances have been made in standard therapies and novel treatments that are showing great potential. These advances reflect careful study performed in the context of clinical trials. Neurosurgeons have played and will continue to play key parts in these studies. In this manuscript, we review clinical trials in neuro-oncology from a neurosurgical point of view and discuss potential roles for neurosurgeons in advancing glioma therapy in the future.",
keywords = "Brain tumor, Clinical trial, Glioblastoma, Glioma, Surgery",
author = "Meghan Murphy and Parney, {Ian F}",
year = "2014",
month = "9",
day = "20",
doi = "10.1007/s11060-014-1569-0",
language = "English (US)",
volume = "119",
pages = "569--576",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Clinical trials in neurosurgical oncology

AU - Murphy, Meghan

AU - Parney, Ian F

PY - 2014/9/20

Y1 - 2014/9/20

N2 - Brain tumors such as diffuse infiltrating gliomas continue to represent a major clinical challenge. Overall survival for patients diagnosed with glioblastoma, the most common primary brain tumor, remains less than 2 years despite intensive multimodal therapy with surgery, radiation, and chemotherapy. However, advances have been made in standard therapies and novel treatments that are showing great potential. These advances reflect careful study performed in the context of clinical trials. Neurosurgeons have played and will continue to play key parts in these studies. In this manuscript, we review clinical trials in neuro-oncology from a neurosurgical point of view and discuss potential roles for neurosurgeons in advancing glioma therapy in the future.

AB - Brain tumors such as diffuse infiltrating gliomas continue to represent a major clinical challenge. Overall survival for patients diagnosed with glioblastoma, the most common primary brain tumor, remains less than 2 years despite intensive multimodal therapy with surgery, radiation, and chemotherapy. However, advances have been made in standard therapies and novel treatments that are showing great potential. These advances reflect careful study performed in the context of clinical trials. Neurosurgeons have played and will continue to play key parts in these studies. In this manuscript, we review clinical trials in neuro-oncology from a neurosurgical point of view and discuss potential roles for neurosurgeons in advancing glioma therapy in the future.

KW - Brain tumor

KW - Clinical trial

KW - Glioblastoma

KW - Glioma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84919421678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919421678&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1569-0

DO - 10.1007/s11060-014-1569-0

M3 - Article

C2 - 25106866

AN - SCOPUS:84919421678

VL - 119

SP - 569

EP - 576

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -